Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

COVID-19 1

Interventions

BNT162 Vaccine 22019-nCoV Vaccine mRNA-1273 2tocilizumab 1sotrovimab 1heterologous prime boost COVID-19 vaccination 1cilgavimab and tixagevimab drug combination 1Therapeutics 1Specimen Handling 1Sodium Chloride 1Radiotherapy 1Losartan 1Janus Kinase Inhibitors 1Ivermectin 1Interleukin-7 1Hydroxychloroquine 1HuMax-IL8 1Ad26COVS1 13-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × COVID-19 × Janus Kinase Inhibitors × Clear all
NCT04404361 2024-06-05

PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer

CTI BioPharma

Phase 2 Terminated
200 enrolled 16 charts

COVID-19

Data powered by HemOnc (CC BY 4.0) Colophon âš¡